Small Molecule Inhibitors of ERG and ETV1 in Prostate Cancer
Abstract
The research involves laboratory studies utilizing xenograft models to test the hypothesis that targeting a member of the ETS transcription factor family with small molecules such as YK-4-279 may effectively treat prostate cancers. In year one Dr. Morrissey was to obtain internal Environmental Health and Safety (EH&S), Institutional Review Board (IRB), Institutional Animal Care and Use Committee (IACUC), Human Research Protections Office (HRPO) and Animal Care and Use Review Office (ACURO) approval. During this time Dr. Aykut Uren at Georgetown University was to screen more potential ETS transcription factor inhibitors for use in animal studies. Dr. Uren was to meet with and supply Dr. Morrissey with the inhibitor. All approvals have been applied for and obtained except for ACURO approval, which we have applied for and are currently awaiting. Dr. Uren has met with and delivered the inhibitor to Dr. Morrissey. The animal studies have been designed. Once ACURO approval is obtained the animal studies will begin.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2013
- Accession Number
- ADA593129
Entities
People
- Colm Morrissey
Organizations
- University of Washington